We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Prometheus Biosciences Inc | NASDAQ:RXDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 199.92 | 194.00 | 199.90 | 0 | 01:00:00 |
From Jun 2022 to Jun 2024
10:19 ET -- Merck & Co. Inc. is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The drug maker said it will acquire Prometheus Biosciences Inc., a clinical-stage biotechnology company specializing in autoimmune disease treatments, for $200 a share, or about $10.8 billion and a 75% premium from where they closed Friday, at $114.01. Prometheus Biosciences's drug candidates include monoclonal antibodies PRA023, PRA052, PR1100 and PR2100 for treating ulcerative colitis, Crohn's disease and other immune-mediated diseases. Dow Jones & Co. owns Factiva. (ada.hui@wsj.com)
(END) Dow Jones Newswires
April 17, 2023 10:34 ET (14:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Prometheus Biosciences Chart |
1 Month Prometheus Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
